Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DCTH - DELCATH SYSTEMS, INC.

IEX Last Trade
11.95
0.095   0.795%

Share volume: 2,724
Last Updated: Fri 27 Dec 2024 08:30:03 PM CET
Surgical and Medical Instrument Manufacturing : -0.06%

PREVIOUS CLOSE
CHG
CHG%
$11.86
0.09
0.80%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
20%
Profitability 25%
Dept financing 28%
Liquidity 15%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.63%
1 Month
6.68%
3 Months
31.03%
6 Months
45.44%
1 Year
194.83%
2 Year
251.03%
Key data
Stock price
$11.95
P/E Ratio 
0.00
DAY RANGE
$11.48 - $11.96
EPS 
$0.00
52 WEEK RANGE
$3.84 - $13.30
52 WEEK CHANGE
$187.74
MARKET CAP 
305.644 M
YIELD 
N/A
SHARES OUTSTANDING 
27.786 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
BETA 
1.07
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$333,238
AVERAGE 30 VOLUME 
$349,675
Company detail
CEO: Gerard J. Michel
Region: US
Website: delcath.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

Delcath Systems, Inc. focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver.

Recent news